Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. [electronic resource]
Producer: 20080924Description: 765-9 p. digitalISSN:- 1592-8721
- Adaptor Proteins, Signal Transducing -- chemistry
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- pharmacology
- Benzamides
- Female
- Fusion Proteins, bcr-abl -- metabolism
- Gene Expression Regulation, Leukemic
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Nuclear Proteins -- chemistry
- Piperazines -- pharmacology
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Pyrimidines -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.